Treatment completion rates of olanzapine and risperidone in long acting injectable formulations for the treatment of schizophrenia: A comparison of single arm open-label studies

被引：0
|
作者：
Ascher-Svanum, H. [1 ]
Montgomery, W. [1 ]
Brnabic, A. [2 ]
Lawson, A. [1 ]
Tomori, O. [1 ]
Coleman, K. [3 ]
Lynch, L. [3 ]
Chen, P. [4 ]
Andersen, S. W. [1 ]
McDonnell, D. P. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, N Ryde, NSW, Australia
[3] Hlth Technol Analysts, Balmain, NSW, Australia
[4] Eli Lilly & Co, Singapore, Singapore
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：161 / 162
页数：2
相关论文
共 50 条
  • [21] Olanzapine in treatment-refractory schizophrenia: Results of an open-label study
    Martin, J
    Gomez, JC
    GarciaBernardo, E
    Cuesta, M
    Alvarez, E
    Gurpegui, M
    JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (11) : 479 - 483
  • [22] An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes
    Cheng, Zhang
    Yuan, Yanbo
    Han, Xue
    Yang, Lei
    Cai, Shangli
    Yang, Fude
    Lu, Zheng
    Wang, Chuanyue
    Deng, Hong
    Zhao, Jingping
    Xiang, Yutao
    Correll, Christoph U.
    Yu, Xin
    JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (10) : 1227 - 1236
  • [23] Long-Acting Injectable Risperidone in the Treatment of Schizophrenia in Special Patient Populations
    Parellada, Eduard
    PSYCHOPHARMACOLOGY BULLETIN, 2007, 40 (02) : 82 - 100
  • [24] Open-label Pilot Study of Long-Acting Injectable Naltrexone Treatment for Cannabis Dependence
    Notzon, Daniel
    Kelly, Meredith
    Choi, Chien-Wen Jean
    Pavlicova, Martina
    Mahony, Amy
    Brooks, Daniel
    Mariani, John
    Levin, Frances
    AMERICAN JOURNAL ON ADDICTIONS, 2017, 26 (03): : 252 - 252
  • [25] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, D.
    Ascher-Svanum, H.
    Bertsch, J.
    Detke, H.
    Mcdonnell, D.
    Witte, M.
    Haro, J.
    VALUE IN HEALTH, 2011, 14 (07) : A288 - A289
  • [26] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, Diego
    Ascher-Svanum, Haya
    Bertsch, Jordan
    Detke, Holland C.
    McDonnell, David
    Maria Haro, Josep
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S357 - S357
  • [27] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
  • [28] OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, P. M.
    Choukour, M.
    Watson, Susan B.
    Brunner, E.
    Ascher-Svanum, H.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 300 - 300
  • [29] Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine
    Potapov, A.
    Eduard, T.
    Sergey, M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 158 - 158
  • [30] EFFICACY OF LONG-ACTING INJECTABLE RISPERIDONE IN DELUSIONAL DISORDER: AN OPEN-LABEL, NATURALISTIC AND PROSPECTIVE STUDY
    Gonzalez Rodriguez, A.
    Molina Andreu, O.
    Imaz Gurrutxaga, M. L.
    Pons Villanueva, A.
    EUROPEAN PSYCHIATRY, 2012, 27
12345